FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.:	APPLICATION NO.:
OC01625K	**10/665,005**
APPLICANT: **Kamil Paruch *et al.***	
FILING DATE: **09/19/2003**	GROUP: 1624

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES	TRANSLATION NO
VR	AL	EP 0 778 277	06/11/1997	EPO				
VR	AM	WO 02/06286	01/24/2002	PCT				
VR	AN	WO 88/04298	06/16/1988	PCT				
	AO							
	AP							

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

VR	AQ	Vesely *et al.*, "Inhibition of Cyclin-Dependent Kinases by Purine Analogues", *Eur. J. Biochem* (1994), **224**: 771-786.
VR	AR	Senderowicz *et al.*, "Phase I Trial of Continuous Infusion Flavopiridol, a Novel Cyclin-Dependent Kinase Inhibitor, in Patients With Refractory Neoplasms", *Journal of Clinical Oncology* (September 1998), **16**(9): 2986-2999.
VR	AS	Meijer *et al.*, "Biochemical and Cellular Effects of Roscovitine, a Potent and Selective Inhibitor of the Cyclin-Dependent Kinases CDC2, CDK2 and CDK5", *Eur. J. Biochem.* (1997), **243**: 527-536.
VR	AT	Bible *et al.*, "Cytotoxic Synergy between Flavopiridol (NSC 649890, L86-8275) and Various Antineoplastic Agents: The Importance of Sequence of Administration", *Cancer Research* (August 15, 1997), **57**: 3375-3380.
VR	AU	Shiota *et al.*, "Synthesis and Structure- Activity Relationship of a New Series of Potent Angiotensin II Receptor Antagonists: Pyrazolo[1,5α]pyrimidine Derivatives", *Chem. Pharm. Bull.* (1999), **47**(7): 928-938.
VR	AV	Yasuo Makisumi, "Studies on the Azaindolizine Compounds. XI. Synthesis of 6,7-Disubstituted Pyrazolo[1,5-α]pyrimidines.", *Chem. Pharm. Bull.* (1962), **10**: 620-626.

EXAMINER	DATE CONSIDERED
Deepak Rao	3/10/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.